Nasdaq · CIK 0000320017
LSTA LISATA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Jan 13, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at LISATA THERAPEUTICS, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 23 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 27,956 | Jan 13, 2025 |
| Jan 9, 2025 | Mohammad Azab director | AGrant or award Common Stock | +15,789 | $0.00 | $0 | 74,469 | Jan 13, 2025 |
| Jan 9, 2025 | Gregory B Brown director | AGrant or award Common Stock | +15,789 | $0.00 | $0 | 65,203 | Jan 13, 2025 |
| Jan 9, 2025 | Kristen K Buck EVP, R&D and CMO | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 87,672 | Jan 13, 2025 |
| Jan 9, 2025 | David J Mazzo President & CEO | AGrant or award Common Stock | +81,000 | $0.00 | $0 | 295,152 | Jan 13, 2025 |
| Jan 9, 2025 | Steven M Klosk director | AGrant or award Common Stock | +15,789 | $0.00 | $0 | 65,359 | Jan 13, 2025 |
| Jan 9, 2025 | Heidi Henson director | AGrant or award Common Stock | +15,789 | $0.00 | $0 | 55,269 | Jan 13, 2025 |
| Jan 9, 2025 | Cynthia Louise Flowers director | AGrant or award Common Stock | +15,789 | $0.00 | $0 | 64,990 | Jan 13, 2025 |
| Jan 9, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | FTax withholding Common Stock | -2,131 | $3.80 | $8,098 | 25,825 | Jan 13, 2025 |
| Jan 9, 2025 | David J Mazzo President & CEO | FTax withholding Common Stock | -9,414 | $3.80 | $36k | 285,738 | Jan 13, 2025 |
| Jan 9, 2025 | Kristen K Buck EVP, R&D and CMO | FTax withholding Common Stock | -2,651 | $3.80 | $10k | 85,021 | Jan 13, 2025 |
| Jan 9, 2025 | Kristen K Buck EVP, R&D and CMO | FTax withholding Common Stock | -2,863 | $3.80 | $11k | 82,158 | Jan 13, 2025 |
| Jan 9, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | FTax withholding Common Stock | -1,137 | $3.80 | $4,321 | 24,688 | Jan 13, 2025 |
| Jan 9, 2025 | David J Mazzo President & CEO | FTax withholding Common Stock | -10,925 | $3.80 | $42k | 274,813 | Jan 13, 2025 |
| Jan 9, 2025 | Kristen K Buck EVP, R&D and CMO | FTax withholding Common Stock | -1,908 | $3.80 | $7,250 | 80,250 | Jan 13, 2025 |
| Jan 9, 2025 | David J Mazzo President & CEO | FTax withholding Common Stock | -7,017 | $3.80 | $27k | 267,796 | Jan 13, 2025 |
| Jan 9, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | FTax withholding Common Stock | -781 | $3.80 | $2,968 | 23,907 | Jan 13, 2025 |
| Jan 10, 2025 | David J Mazzo President & CEO | FTax withholding Common Stock | -3,106 | $3.73 | $12k | 264,690 | Jan 13, 2025 |
| Jan 10, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | FTax withholding Common Stock | -416 | $3.73 | $1,552 | 23,491 | Jan 13, 2025 |
| Jan 10, 2025 | Kristen K Buck EVP, R&D and CMO | FTax withholding Common Stock | -456 | $3.73 | $1,701 | 79,794 | Jan 13, 2025 |
| Jan 9, 2025 | David J Mazzo President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 13, 2025 |
| Jan 9, 2025 | Kristen K Buck EVP, R&D and CMO | AGrant or award Stock Option (Right to Buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jan 13, 2025 |
| Jan 9, 2025 | James Nisco SVP, Fin/Treas, Chief Actg Off | AGrant or award Stock Option (Right to Buy)derivative | +7,000 | $0.00 | $0 | 7,000 | Jan 13, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Mohammad Azabdirector
- Gregory B Browndirector
- Kristen K BuckEVP, R&D and CMO
- Cynthia Louise Flowersdirector
- Heidi Hensondirector
- Steven M Kloskdirector
- David J MazzoPresident & CEO
- James NiscoSVP, Fin/Treas, Chief Actg Off
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.